VGXI Enters Into Licensing Agreement with NTC to Use HyperGRO™ Fermentation Technology

Share Article

VGXI has entered into a licensing agreement with Nature Technology Corporation to use their HyperGRO™ Fermentation Technology following the successful scale up of two cGMP fermentation runs.

VGXI, Inc., a leading provider of DNA plasmid contract manufacturing and development services, announced today that it has entered into a licensing agreement with Nature Technology Corporation (NTC) for the use of their HyperGRO™ fermentation technology.

According to Dorothy Peterson, Vice President of Operations at VGXI, “We are excited about the opportunity to add NTC’s HyperGRO™ fermentation technology as a viable option for clients requiring higher plasmid yields due to trial design and/or low yielding plasmids. We are also excited to now have the ability to offer the option of an antibiotic-free selection vector, especially to European and Asian clients where this type of vector is becoming preferred”.

The agreement is a non-exclusive, royalty bearing, non-sublicensable license to market, sell, and perform the contract research and development and product manufacturing services utilizing NTC’s HyperGRO™ fermentation technology including their antibiotic-free selection vector.

In October, VGXI successfully scaled-up and manufactured two large-scale cGMP fermentation runs using NTC’s technology. VGXI was able to achieve plasmid yields of up to 1.8 g/L at a 320L fermentation scale, the largest scale yet using the HyperGRO™ technology according to NTC. Results of these two fermentation runs will be presented at the DNA Vaccines meeting in San Diego, California held December 5-7, 2012.

About HyperGRO™ Fermentation Technology
NTC’s HyperGRO™ fermentation process and media are used routinely for production of gene therapy vectors and DNA vaccines. Improvements in fed-batch fermentation resulted in plasmid DNA yields of up to 2.6g/L. This process is also compatible with NTC’s antibiotic-free sucrose plasmid selection system.

About VGXI, Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under GMP conditions for client clinical studies in the US and Europe, and its GMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI's ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible GMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset. For more information, visit

About Nature Technology
Nature Technology Corporation is a biotechnology company that provides industry partners with world class technology platforms, including safe and efficacious non-viral vectors (plasmids) and processes for gene therapy and DNA vaccination vector production. NTC also provides cost effective outsourcing of product development services including synthetic gene design, vector construction, plasmid DNA manufacturing and recombinant proteins. For information, visit

Cautionary Factors That May Affect Future Results - Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements do not relate strictly to historical or current facts and can therefore be identified as such. They include words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Colvin
Email >
Visit website